175 related articles for article (PubMed ID: 16897434)
1. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
[TBL] [Abstract][Full Text] [Related]
2. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
3. Long-term transvaginal ultrasonographic endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment.
Nahari C; Tepper R; Beyth Y; Flex D; Figer A; Cohen I
Gynecol Oncol; 1999 Aug; 74(2):222-6. PubMed ID: 10419735
[TBL] [Abstract][Full Text] [Related]
4. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients.
Cohen I; Beyth Y; Azaria R; Flex D; Figer A; Tepper R
BJOG; 2000 Sep; 107(9):1083-7. PubMed ID: 11002949
[TBL] [Abstract][Full Text] [Related]
5. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Maturitas; 2008 Apr; 59(4):387-93. PubMed ID: 18490117
[TBL] [Abstract][Full Text] [Related]
7. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Morales L; Timmerman D; Neven P; Konstantinovic ML; Carbonez A; Van Huffel S; Ameye L; Weltens C; Christiaens MR; Vergote I; Paridaens R
Ann Oncol; 2005 Jan; 16(1):70-4. PubMed ID: 15598941
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology.
Morales L; Paridaens R; Timmerman D; Neven P
Clin Cancer Res; 2006 Sep; 12(18):5603. PubMed ID: 17000698
[No Abstract] [Full Text] [Related]
9. Aromatase inhibitors and the endometrium.
Cohen I
Maturitas; 2008 Apr; 59(4):285-92. PubMed ID: 18448280
[TBL] [Abstract][Full Text] [Related]
10. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.
Kieback DG; Harbeck N; Bauer W; Hadji P; Weyer G; Menschik T; Hasenburg A
Gynecol Oncol; 2010 Dec; 119(3):500-5. PubMed ID: 20832103
[TBL] [Abstract][Full Text] [Related]
11. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I
Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946
[TBL] [Abstract][Full Text] [Related]
12. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
15. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow.
Develioğlu OH; Omak M; Bilgin T; Esmer A; Tüfekçi M
Gynecol Oncol; 2004 May; 93(2):328-35. PubMed ID: 15099941
[TBL] [Abstract][Full Text] [Related]
16. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
17. Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399.
Paridaens R; Morales L; Neven P; Timmerman D
Ann Oncol; 2005 Aug; 16(8):1402-3; author reply 1402-3. PubMed ID: 15870087
[No Abstract] [Full Text] [Related]
18. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen.
Lindahl B; Andolf E; Ingvar C; Liedman R; Ranstam J; Willén R
Anticancer Res; 1997; 17(5B):3821-4. PubMed ID: 9427787
[TBL] [Abstract][Full Text] [Related]
19. Endometrial thickening in postmenopausal breast cancer patients taking tamoxifen: a cross-sectional study.
Sinawat S; Chiyabutra T
J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S59-63. PubMed ID: 21218592
[TBL] [Abstract][Full Text] [Related]
20. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients.
Kavak ZN; Binöz S; Ceyhan N; Pekin S
Acta Obstet Gynecol Scand; 2000 Jul; 79(7):604-7. PubMed ID: 10929963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
